Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7th

SANTA MONICA, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. ("Opiant") OPNT, a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it will report its financial results for the third quarter and nine months ended September 30, 2018, after the market close, and will host a corporate update conference call and webcast on Wednesday, November 7, 2018, at 4:30 p.m. Eastern Time.

About Opiant Pharmaceuticals, Inc.
Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose. NIDA, a division of the NIH, describes addictive disorders as chronic relapsing brain diseases which burden society at both the individual and community levels. With its innovative opioid antagonist nasal delivery technology, Opiant is positioned to become a leader in these treatment markets. Opiant's first drug overdose product, NARCAN® Nasal Spray, is approved for marketing in the U.S. and Canada by its commercialization partner, Adapt Pharmaceuticals, now owned by Emergent BioSolutions, Inc.  For more information please visit: www.opiant.com.

CONTACTS:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
(617) 535-7746